Drug intelligence / Profile preview

Tumor killer cells (TKC)

Development stage: Preclinical
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Cell Therapies
Administration: Infusion

Overview

Tumor killer cells (TKC) are an adoptive cell therapy consisting of mixed cultures of two innate immune cells: natural killer (NK) cells and gamma delta T (γδT) cells. These cells are co-activated and co-cultured ex-vivo using a specific TKC technology. The adoptive transfer of TKC is designed to exert a strong anti-tumor effect through the synergistic action of NK cells and γδT cells. It is being investigated for the treatment of advanced non-small cell lung cancer (NSCLC).

Other names: Tumor killer cells

Targets

ULBP1 (UL16-binding protein 1)NCR3LG1 (Natural cytotoxicity triggering receptor 3 ligand 1)

Beyond the preview

Go deeper on Tumor killer cells (TKC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tumor killer cells (TKC).

Explore the full profile